Nanxue Medical's Multi-Parameter Chronic Disease Monitor Achieves Rapid Market Success Within Six Months of Launch

The Yellow Emperor’s Inner Canon states: “The sage does not treat those who are already ill, but those who are not yet ill; he does not restore order to chaos that has already arisen, but prevents chaos before it occurs.” Wang Zhonghan, Chairman of Guangzhou Nanxue Medical Instruments Co., Ltd., strongly concurs with this philosophy. With the aging population and the implementation of the “Healthy China 2030” Planning Outline, the field of chronic disease management has entered a golden period of development.

Meanwhile, Wang Zhonghan recognized that significant pain points persisted in the field of chronic disease management, despite it being a high-growth sector. In 2018, China had over 300 million patients with chronic diseases; deaths attributable to these conditions accounted for 80% of all disease-related mortality, and the associated disease burden represented 70% of the total national disease burden. “Due to the large number of chronic disease patients, high rates of disability and mortality, and an underdeveloped primary healthcare system, the chronic disease management market in China continues to face numerous challenges.”

“Early prevention, early detection, and early treatment” is the golden rule of chronic disease management. Targeting the gap in chronic disease information monitoring, Guangzhou Nanxue Medical Instruments Co., Ltd. dedicated three years to research and development, launching the Nanxue Multi-functional Health Checkup Kiosk. In its first month on the market, sales revenue exceeded one million yuan. In the six months since its launch, the kiosk’s monthly sales revenue has grown exponentially.

Traditional testing instruments can only detect one indicator at a time, while the multi-functional health checkup machine developed by Nanxue Medical Instruments can simultaneously detect multiple indicators using just a drop of fingertip blood the size of a grain of rice.Blood Pressure, Heart Rate, Blood Glucose, Uric Acid, Cholesterol, TriglyceridesSix indicators. These six indicators correspond to diseases such as coronary heart disease, diabetes, gout, stroke, and cerebral infarction. In the future, the multi-functional health checkup machine will undergo hardware and software upgrades to add more features, such as ECG detection.

The multi-functional health checkup kiosk is the result of three years of R&D by the team at Guangzhou Nanxue Medical Instruments Co., Ltd. The company boasts a senior research and development team comprising nearly 100 highly skilled professionals with multidisciplinary expertise in biomedicine, computer science, artificial intelligence, electronics, optics, and mechanical engineering. Equipped with an built-in AI chip, this device offers detection speeds more than ten times faster than similar products and enables instant data transmission and sharing. By pairing with a smartphone, it allows for real-time monitoring of family members' health. The entire process—including comprehensive six-parameter testing, backend data analysis, result display, and synchronization of health charts and records to the user's mobile phone—can be completed within seven minutes, with a detection accuracy rate exceeding 90%.

The home-use version enables users to conduct tests anytime, anywhere, facilitating self-management. In contrast, the commercial version is a professional medical device for chronic disease testing, designed specifically for medical and pharmaceutical endpoints such as pharmacies and clinics. It aims to address the marketing pain points associated with traditional pharmacy-based chronic disease management. By performing health assessments for customers and recommending the most suitable products based on the results, the multifunctional commercial health screening kiosk helps medical and pharmaceutical endpoints generate a steady stream of customer traffic and business opportunities in chronic disease management.

Guangzhou Nanxue Medical Instruments Co., Ltd. has created the “Smart Nanxue” internet health platform. Test data from multi-functional health checkup kiosks are synchronously uploaded to this platform, allowing users and their families to access health diagnostic reports at any time. Furthermore, the “Smart Nanxue” platform has established cooperative agreements with authoritative domestic medical institutions and a team of senior medical experts, enabling users to receiveFamily Physician, Health Consultant, Chronic Disease Consultation, Pharmaceutical Shopping Guide, Remote Monitoringand other online value-added services, safeguarding family health.

Guangzhou Nanxue Medical Instruments Co., Ltd. has partnered with two hospitals in Guangdong Province to provide remote diagnosis and treatment services. Additionally, Nanxue Group is developing targeted therapeutic agents for six diagnostic indicators, leveraging its multi-functional health screening devices to drive the growth of its pharmaceutical subsidiary.

Currently, the primary revenue source for Guangzhou Nanxue Medical Instruments Co., Ltd. is the sales of its multi-functional health examination machines. Wang Zhonghan stated, “Remote consultation and pharmaceutical sales will generate substantial revenue. Moving forward, the company will continue to expand its pool of physicians on the platform and provide users with appropriate medications through independent research and development as well as collaborations with pharmaceutical companies.”

In addition, Nanxue Medical Instruments is collaborating with township-level medical institutions to deploy multi-functional health examination kiosks in township clinics. Through the Smart Nanxue Platform, it provides remote diagnosis and treatment services to patients in these areas, thereby alleviating the shortage of primary healthcare resources.

Founded in 2003, Nanxue Group has been actively engaged in the life and health sector, adhering to its mission of “creating a healthy and beautiful new life” and striving to improve human health and well-being. Over more than a decade, Nanxue Group has established deep cooperative relationships with approximately 100,000 pharmacies across China. In addition, the group has built its own sales channel—Linhe Pharmaceutical Chain. As a result, upon its release, the commercial multi-functional health screening kiosk was rapidly deployed to over 10,000 pharmacies in 15 provinces and municipalities nationwide. The home-use multi-functional health screening kiosk is marketed and sold through media channels such as Phoenix News and Jinri Toutiao.

Wang Zhonghan stated that there is still significant room for growth in the sales of multi-functional health check-up machines. With 400 million households across China, it is estimated that Nanxue’s multi-functional health check-up machine can achieve a market share of 30%. These devices provide more innovative and systematic smart healthcare solutions for the prevention, control, and treatment of chronic diseases, enabling users to engage in early prevention and early treatment, thereby ensuring quality of life and offering enhanced health management services aligned with the concept of “preventive treatment.” Nanxue’s mission and vision are to increase human lifespan by one year and to make unremitting efforts toward creating a healthy and beautiful new life.

In recent years, blood testing has gradually become the primary method for cancer genetic testing. Within four to five years, Guangzhou Nanxue Medical Instruments Co., Ltd. will develop cancer genetic testing devices. Wang Zhonghan stated, “In China, many cancer patients are diagnosed at intermediate or advanced stages, having missed the optimal window for treatment. By incorporating cancer genetic testing capabilities, users can perform tests at home at any time, which could significantly improve survival rates for cancer patients.”

Wang Zhonghan stated, “Blood is a very important diagnostic indicator, extending beyond the realm of chronic disease management. In the future, Guangzhou Nanxue Medical Instruments Co., Ltd. will continue to advance blood testing technologies for detecting prostate diseases, infectious diseases, and other conditions, thereby making greater contributions to human health.”

According to the "Analysis of the Current Status and Development Trends of China's Chronic Disease Management Market in 2018" released by Qianzhan Industry Research Institute, China has increased its investment and support for chronic disease management in recent years. In 2016, China's expenditure on chronic diseases was approximately RMB 3,244.15 billion, accounting for about 70% of the total health expenditure. If 10% of this amount could be converted into spending on chronic disease management services in the future, the market size would reach RMB 324.4 billion, indicating huge development potential. Wang Zhonghan stated, "With the advent of population aging in China, the chronic disease management market is expected to grow at an annual rate of 10%."